Every round on record, with the sources behind each and the investors on them.
A research-focused startup developing temperature-responsive magnetic nanoparticles
segnos.co.jp千葉県千葉市中央区HealthtechFounded 2024
3 sources · checked 7 times, last 3h ago
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The company release identifies BP Capital’s fund as the share-allotment recipient, while nstartup calls BP Capital the lead. The funding amount is undisclosed.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Pre-A pre-Series A | n/a | 2026-10-22 | bp Ventures | No recent discussion |
3 sources · checked 7 times, last 3h ago [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 3 sources
The company release identifies BP Capital’s fund as the share-allotment recipient, while nstartup calls BP Capital the lead. The funding amount is undisclosed. | ||||
SEGNOS develops and sells temperature-responsive magnetic nanoparticles and diagnostic technologies that help medical and research users separate and detect tiny biomarkers faster and more sensitively.
SEGNOS says conventional micron-scale magnetic beads are difficult to disperse and can cause pipetting errors, while its roughly 100-nanometer temperature-responsive particles are designed to improve capture, separation speed and sensitivity for applications such as blood-drop testing and early biomarker detection. The October 2026 Pre-Series A investment from BP Capital's TUAT 1 fund, whose amount was not disclosed, is intended to accelerate healthcare-testing and in-vitro-diagnostic R&D, alongside traction including a joint study with Tokyo Metropolitan Institute of Gerontology and a ¥10 million grant from the Ogasawara Toshiaki Memorial Foundation.
Checked against 8 sources 6d ago
Also named as backers in company research: JNC株式会社, TUAT１号投資事業有限責任組合